obinutuzumab,zanubrutinib
roche,beigene
['obinu', 'rosewood', 'zanubrutinib', 'follicular', 'lymphoma', 'lymsm']
congress #eha2023 | shows analysis of the phii rosewood study of zanubrutinib + obinutuzumab in r/r follicular #lymphoma. n=217. est os rate at 24 months = 77.3% (zan + obin) &amp; 71.4% (obin), with median os =nr (zan + obin) &amp; 34.6 months (obin). #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm